Glycine Treatment of Prodromal Symptoms

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00268749

Enrollment

Registered

2005-12-22

Start date

2002-07-31

Completion date

2004-11-30

Last updated

2012-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Interventions

DRUGglycine

0.8 g/kg/day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

14 Years to 35 Years

Healthy volunteers

Inclusion criteria

* age 14-35 * meets SIPS criteria for psychosis prodrome

Exclusion criteria

* current antipsychotic medication * more than 4 weeks of antipsychotic medication lifetime

Design outcomes

Primary

Measure	Time frame
Scale Of Prodromal Symptoms total score	8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026